Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial

医学 人口 内科学 临床终点 安慰剂 临床试验 物理疗法 病理 替代医学 环境卫生
作者
Gıancarlo Comı,Ludwig Kappos,Krzysztof Selmaj,Amit Bar‐Or,Douglas L. Arnold,Lawrence Steinman,Hans‐Peter Hartung,Xavier Montalbán,Eva Havrdová,Bruce Cree,James K. Sheffield,Neil Minton,Kartik Raghupathi,Ning Ding,Jeffrey A. Cohen
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:18 (11): 1009-1020 被引量:236
标识
DOI:10.1016/s1474-4422(19)30239-x
摘要

Ozanimod, a sphingosine 1-phosphate receptor modulator, selectively binds to receptor subtypes 1 and 5 with high affinity. The RADIANCE phase 2 study showed that ozanimod had better efficacy than placebo on MRI measures, with a favourable safety profile, in participants with relapsing multiple sclerosis. The SUNBEAM study aimed to assess the safety and efficacy of ozanimod versus intramuscular interferon beta-1a in participants with relapsing multiple sclerosis.SUNBEAM was a randomised, double-blind, double-dummy, active-controlled phase 3 trial done at 152 academic medical centres and clinical practices in 20 countries. We enrolled participants aged 18-55 years with relapsing multiple sclerosis, baseline expanded disability status scale (EDSS) score of 0·0-5·0, and either at least one relapse within the 12 months before screening or at least one relapse within 24 months plus at least one gadolinium-enhancing lesion within 12 months before screening. Participants were randomly assigned 1:1:1 by a blocked algorithm stratified by country and baseline EDSS score to at least 12 months treatment of either once-daily oral ozanimod 1·0 mg or 0·5 mg or weekly intramuscular interferon beta-1a 30 μg. Participants, investigators, and study staff were masked to treatment assignment. The primary endpoint was annualised relapse rate (ARR) during the treatment period and was assessed in the intention-to-treat population. Safety was assessed in all participants according to the highest dose of ozanimod received. This trial is registered at ClinicalTrials.gov, number NCT02294058 and EudraCT, number 2014-002320-27.Between Dec 18, 2014, and Nov 12, 2015, 1346 participants were enrolled and randomly assigned to ozanimod 1·0 mg (n=447), ozanimod 0·5 mg (n=451), or interferon beta-1a (n=448). 91 (6·8%) participants discontinued the study drug (29 in the ozanimod 1·0 mg group; 26 in the ozanimod 0·5 mg group; and 36 in the interferon beta-1a group). Adjusted ARRs were 0·35 (0·28-0·44) for interferon beta-1a, 0·18 (95% CI 0·14-0·24) for ozanimod 1·0 mg (rate ratio [RR] of 0·52 [0·41-0·66] vs interferon beta-1a; p<0·0001), and 0·24 (0·19-0·31) for ozanimod 0·5 mg (RR 0·69 [0·55-0·86] vs interferon beta-1a; p=0·0013). Few ozanimod-treated participants discontinued treatment because of adverse events (13 [2·9%] who received ozanimod 1·0 mg; seven [1·5%] who received ozanimod 0·5 mg; and 16 [3·6%] who received interferon beta-1a). No first-dose, clinically significant bradycardia or second-degree or third-degree atrioventricular block was reported. The incidence of serious adverse events was low and similar across treatment groups (13 [2·9%] participants who received ozanimod 1·0 mg; 16 [3·5%] who received ozanimod 0·5 mg; and 11 [2·5%] who received interferon beta-1a). No serious opportunistic infections occurred in ozanimod-treated participants.In participants with relapsing multiple sclerosis treated for at least 12 months, ozanimod was well tolerated and demonstrated a significantly lower relapse rate than interferon beta-1a. These findings provide support for ozanimod as an oral therapy for individuals with relapsing multiple sclerosis.Celgene International II.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
碧蓝的盼夏完成签到,获得积分10
4秒前
AU完成签到 ,获得积分10
5秒前
研友_yLpYkn完成签到,获得积分10
6秒前
兴奋的定帮完成签到 ,获得积分0
7秒前
一叶知秋应助大橙子采纳,获得10
8秒前
9秒前
金蛋蛋完成签到 ,获得积分10
9秒前
马琛尧完成签到 ,获得积分10
11秒前
一行白鹭上青天完成签到 ,获得积分10
15秒前
帅气的宽完成签到 ,获得积分10
16秒前
lixoii完成签到 ,获得积分10
18秒前
萌萌许完成签到,获得积分10
18秒前
sunce1990完成签到 ,获得积分10
21秒前
Bin_Liu完成签到,获得积分20
22秒前
宇老师完成签到,获得积分10
22秒前
研友_VZG7GZ应助马琛尧采纳,获得10
23秒前
安安的小板栗完成签到,获得积分10
26秒前
123_完成签到,获得积分10
28秒前
NexusExplorer应助大橙子采纳,获得10
29秒前
上善若水完成签到 ,获得积分10
31秒前
qiqi发布了新的文献求助10
35秒前
35秒前
英俊的铭应助cm采纳,获得10
36秒前
37秒前
量子星尘发布了新的文献求助10
37秒前
affy210310完成签到,获得积分10
38秒前
名字不好起完成签到,获得积分10
38秒前
齐朕完成签到,获得积分10
39秒前
大橙子发布了新的文献求助10
41秒前
speed完成签到 ,获得积分10
42秒前
RYK完成签到 ,获得积分10
43秒前
44秒前
cm发布了新的文献求助10
48秒前
50秒前
50秒前
50秒前
50秒前
50秒前
大力水手完成签到,获得积分0
52秒前
54秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038157
求助须知:如何正确求助?哪些是违规求助? 3575869
关于积分的说明 11373842
捐赠科研通 3305650
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022